Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

NANOPARTICLES FOR THERAPY AND DIAGNOSIS OF ALZHEIMER DISEASE

NAD

The search for effective therapies and early detection strategies for Alzheimer’s Disease (AD), the major cause of dementia in Europe, is imperative. It is known that β-amyloid (Aβ) peptide plays a central role in neurodegeneration. In AD brain, Aβ is released in a soluble form that progressively becomes insoluble forming aggregates; extracellular...

Funding Programme
Start Date
End Date
Total Funding
€ 14 365 090

Nanosystems for the early Diagnosis of Neurodegenerative diseases

NADINE

Medical diagnosis is currently undergoing a major revolution due to the fast discovery of molecular biomarkers, and the development of multimodal “metabiomarker” signatures. Progress, however, is hindered by low abundance of many biomarkers of interest in body fluids, in absolute concentration and with regard to other biomolecules. The aim of the...

Funding Programme
Start Date
End Date
Total Funding
€ 11 702 928
European Countries Involved

Non-Animal Platform for Nanoparticle-Based Delivery across the blood-brain barrier Interface with Vehicle Evolution

NAP4DIVE

The blood-brain barrier (BBB) is a major obstacle in treating diseases of the central nervous system (CNS) such as Parkinson's, Alzheimer's, Schizophrenia and brain cancer, affecting 180 million Europeans with less than 5% of current candidate drugs effectively reaching the brain. NAP4DIVE strives to revolutionize the traditionally expensive and...

Funding Programme
Start Date
End Date
Total Funding
€ 7 767 276
European Countries Involved

Non-invasive dynamic neural control by laser-based technology

NEUROPA

Europe faces an enormous human toll of brain disorders, with an estimated 83 million people affected, and economic costs amounting to approximately €800 billion. Drug treatments for brain disorders prove often less than effective with a lack of selective cell targeting. A failure to develop new drugs has led major Pharmaceutical companies to...

Funding Programme
Start Date
End Date
Total Funding
€ 3 604 780
European Countries Involved

OLIGOPEPTIDASE INHIBITORS IN BRAIN FUNCTION AND DYSFUNCTION: TOWARDS NEW THERAPEUTIC STRATEGIES FOR NEUROPROTECTION

NEUROPRO

At present more than 5 million people in the EU suffer from dementia and other neurodegenerative diseases and that number will grow as the average age of the population continues to increase. The efficacy of current medicines is limited and new therapeutic targets are sorely needed. Several independent lines of evidence have established an...

Funding Programme
Start Date
End Date
Total Funding
€ 6 290 178
European Countries Involved

Personalised medicine approach for novel microglia-associated genetic variants in Alzheimer’s disease

PMG-AD

The role of inflammation and innate immune system in Alzheimer’s disease (AD) has been recently emphasized as GWAS and WES studies as well as functional studies have identified several AD-associated genes, including TREM2, ABI3, and PLCG2 that are expressed selectively or preferentially in microglia in the brain. These genetic and functional...

Funding Programme
Start Date
End Date
Total Funding
€ 1 400 000
European Countries Involved

Personalized Recommendations for Neurodegenerative Disease

VirtualBrainCloud

The annual worldwide cost of Alzheimer’s dementia was 777.81 billion Euro in 2015. This number will rise to 7.41 trillion Euro in 2050. Early diagnosis would save up to $7.9 trillion in medical and care costs by 2050 in the US alone. However, the emergent pathology is highly variable across people, necehighly variable across people, necessitating...

Funding Programme
Start Date
End Date
Total Funding
€ 15 016 343
European Countries Involved

PRECISION MEDICINE PLATFORM IN NEURODEGENERATIVE DISEASE

PROMINENT

Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Comorbidities with these conditions are frequent and a major obstacle to optimal diagnosis and management. Recent advances...

Funding Programme
Start Date
End Date
Total Funding
€ 6 069 750
European Countries Involved

Preservation and Efficacy of Music and Singing in Ageing, Aphasia, and Alzheimer’s Disease

PREMUS

For the human brain, music is a highly complex and versatile stimulus that is closely linked to speech, executive-motor, emotion, and memory networks. In severe ageing-related neurological disorders, such as post-stroke aphasia and Alzheimer’s disease (AD) dementia, music and singing may provide a valuable alternative route to verbal and emotional...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 967
European Countries Involved

PROMOTING ACTIVE AGEING: FUNCTIONAL NANOSTRUCTURES FOR ALZHEIMER’S DISEASE AT ULTRA-EARLY STAGES.

PANA

Alzheimer’s disease (AD) is the leading cause of dementia and loss of autonomy in the elderly, implying a progressive cognitive decline and limitation of social activities. Progressive aging of EU population will increase the magnitude of this problem in the next decades. Currently, there is not an effective method for the early diagnosis of AD...

Funding Programme
Start Date
End Date
Total Funding
€ 7 775 973
European Countries Involved

PROMOTING MENTAL WELLBEING IN THE AGEING URBAN POPULATION: DETERMINANTS, POLICIES AND INTERVENTIONS IN EUROPEAN CITIES

MINDMAP

Major depressive disorder, dementia, anxiety disorders, and substance abuse affect a substantial part of the European older population. Over 70% of Europeans reside in cities, and this percentage will increase in the next decades. Urbanization and ageing have enormous implications for public mental health. Cities pose major challenges for older...

Funding Programme
Start Date
End Date
Total Funding
€ 5 743 160
European Countries Involved

Propagation behaviour of peripheral amyloid-β towards brain structures: effects of the blood-brain barrier

PROP-AD

Alzheimer's disease is a disease in which specific peptides, so-called beta-amyloids, accumulate in the brain, leading to the destruction of neurons and the resulting clinical functional effects, e.g. memory and orientation problems. Discussions are ongoing as to whether or not Alzheimer's disease may be transmissible between individuals and could...

Funding Programme
Start Date
End Date
Total Funding
€ 1 746 751
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).